Incyte (INCY) Misses Q4 EPS by 76c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs
February 8, 2022 7:00 AM ESTTotal product and royalty revenues of $813 million (+20%) in Q421 and $2.891 billion (+17%) in FY21 Jakafi® (ruxolitinib) net product revenues of $592 million (+15%) in Q421 and $2.135 billion (+10%) in FY21; Jakafi guidance range of $2.3 to $2.4 billion for 2022 Successful U.S. launch of Opzelura (ruxolitinib) cream in atopic dermatitis with nearly 19,000 patients treated from launch (October 11th) through the end of the year Vitiligo is the next substantial growth opportunity for ruxolitinib cream under Priority Review in the U.S. and under review in Europe
Conference Call and Webcast Scheduled Today at 8:00 a.m.... More
